Welcome to our dedicated page for Harmony Biosciences Holdings SEC filings (Ticker: HRMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Harmony Biosciences Holdings, Inc. filings document a commercial-stage pharmaceutical issuer focused on rare neurological diseases and its WAKIX-centered operating results. Form 8-K reports furnish quarterly and annual financial results, preliminary net product revenue, revenue guidance, investor presentations, and clinical-program updates.
Governance filings include definitive proxy materials for annual meeting matters, board elections, executive compensation, and shareholder voting procedures. Material-event reports also record executive appointments, separations, compensatory arrangements, board changes, Regulation FD disclosures, and exhibit-based updates related to the company’s business and pipeline.
Harmony Biosciences Holdings, Inc. is calling a virtual 2026 annual meeting on May 14, 2026 at 1:00 p.m. Eastern Time to consider key governance and compensation matters. Holders of common stock at the March 17, 2026 record date, when 57,867,389 shares were outstanding, may vote online.
Stockholders will vote on electing four Class III directors (Andreas Wicki, Geno Germano, Troy Ignelzi and Ron Philip) to terms ending at the 2029 meeting, ratifying Deloitte & Touche LLP as independent auditor for the year ending December 31, 2026, and approving on a non-binding basis the compensation of named executive officers.
The board, which is largely independent and organized into audit, compensation, and nominating and corporate governance committees, emphasizes pay-for-performance through base salary, annual cash incentives and equity awards. 2025 bonuses for named executives were generally paid at or near target based on revenue, clinical, transaction, financial and talent goals, and the company maintains an anti-hedging policy and a clawback policy on incentive pay.
Harmony Biosciences Holdings, Inc. appointed Peter Anastasiou as Senior Executive Vice President and Chief Operating Officer, effective April 2, 2026, and he resigned from the board to assume the executive role. The company also appointed Troy Ignelzi as a Class III director and announced that Antonio Gracias will not stand for re-election at the 2026 annual meeting.
Under his employment agreement, Anastasiou will receive a $600,000 annual base salary, a target annual bonus equal to 55% of salary, and a stock option award with a grant date fair value of $3,700,000, together with severance protections and customary restrictive covenants. Ignelzi will serve on the Audit and Compensation Committees and is deemed an independent director, while the board has nominated Geno J. Germano for election at the 2026 annual meeting.
Harmony Biosciences Holdings Inc: an amendment to a Schedule 13G/A reports that The Vanguard Group holds 0 shares of common stock, representing 0 % of the class. The filing explains an internal realignment effective January 12, 2026 that led certain Vanguard subsidiaries to report beneficial ownership separately.
Harmony Biosciences describes a growing neuroscience business centered on WAKIX, its non-scheduled narcolepsy therapy, and an expanding rare disease pipeline. Net product revenue from WAKIX reached $868.5 million in 2025, within a U.S. narcolepsy market estimated at $3.1 billion.
WAKIX now covers excessive daytime sleepiness and cataplexy in adults and children six and older, with about 8,500 patients on therapy in Q4 2025. The company is advancing next‑generation pitolisant formulations (Pitolisant GR and HD), late‑stage programs in Prader–Willi syndrome and myotonic dystrophy type 1, and a rare epilepsy franchise led by EPX‑100 Phase 3 trials in Dravet and Lennox‑Gastaut syndromes.
Harmony Biosciences Holdings, Inc. reported strong 2025 results driven by its narcolepsy drug WAKIX. Net product revenue reached $868.5 million for 2025, up from $714.7 million, while Q4 2025 revenue was $243.8 million, a 21% year-over-year increase.
GAAP net income was $158.7 million for 2025, or $2.71 per diluted share, compared with $145.5 million, or $2.51 per share, in 2024. Non-GAAP adjusted net income rose to $211.0 million, or $3.60 per diluted share. The company ended 2025 with $882.5 million in cash, cash equivalents and investments, up from $576.1 million.
Harmony reiterated 2026 WAKIX net revenue guidance of $1.0–$1.04 billion, highlighting expectations for blockbuster status in narcolepsy. Management also emphasized a late-stage pipeline, including five Phase 3 trials, a planned pitolisant GR NDA submission targeted for Q2 2026, and an ongoing Phase 1 trial of an orexin-2 agonist.
FMR LLC has filed an amended Schedule 13G reporting beneficial ownership of 3,112,812.16 shares of Harmony Biosciences Holdings, Inc. common stock, representing 5.4% of the class as of the reporting date.
FMR LLC reports sole voting power over 3,109,042 shares and sole dispositive power over 3,112,812.16 shares, with no shared voting or dispositive power. Abigail P. Johnson is also listed as a reporting person with sole dispositive power over 3,112,812.16 shares and no voting power. The filers certify the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Harmony Biosciences.
Harmony Biosciences Holdings, Inc. disclosed that Chief Financial Officer Sandip Kapadia sold 3,746 shares of common stock on January 26, 2026 in an open-market transaction coded as a sale. The shares were sold at a weighted average price of $37.152 under a pre-arranged Rule 10b5-1 trading plan.
After this transaction, Kapadia directly beneficially owned 24,521 shares of Harmony Biosciences common stock. The filing also notes that a previous Form 4 filed on January 26, 2026 had inadvertently misstated the post-transaction share balance, which has been corrected in this report.
Harmony Biosciences Holdings, Inc. chief financial officer Sandip Kapadia reported several equity compensation transactions. On January 22, 2026, he received a stock option for 42,600 shares of common stock at an exercise price of $36.76, and 12,200 restricted stock units (RSUs), both vesting over multiple years subject to continued service.
On January 24, 2026, 3,813 RSUs previously granted on January 24, 2024 vested and converted into the same number of common shares. Of these, 2,239 shares were withheld at $36.82 per share to cover taxes, leaving 1,574 shares of common stock directly held. On January 25, 2026, 4,725 RSUs from a January 25, 2025 grant vested, with 2,553 shares withheld for taxes at $36.82 per share and 2,172 shares retained as common stock.
Harmony Biosciences Chief Strategy Officer Andrew Serafin reported multiple equity compensation transactions and related tax withholdings. On January 22, 2026, he received a stock option for 42,600 shares of common stock at an exercise price of $36.76 per share and 12,200 restricted stock units (RSUs), both vesting over several years subject to continued service. On January 24 and 25, 2026, previously granted RSUs vested, converting into 2,500 and 2,600 shares of common stock, respectively. At each vesting date, the issuer withheld 1,116 and 1,126 shares at a price of $36.82 per share to cover income tax obligations, leaving Serafin with directly held common shares and remaining unvested RSUs that continue to vest in annual installments.
Harmony Biosciences (HRMY) chief medical officer Budur Kumar reported new equity awards and routine tax withholding transactions. On January 22, 2026, Kumar received a stock option for 42,600 shares of common stock at an exercise price of $36.76, vesting 25% on January 22, 2027 with the remainder vesting quarterly until the fourth anniversary, subject to continued service. On the same date, Kumar was granted 12,200 restricted stock units (RSUs) that vest in four equal annual installments beginning January 22, 2027.
On January 24 and 25, 2026, portions of earlier RSU grants vested, converting 2,188 and 2,662 RSUs into common shares. The company withheld 1,153 and 1,372 shares, respectively, at a price of $36.82 per share to satisfy income tax obligations, leaving 1,035 and 1,290 shares directly held after each event.